Clinical trials: Envafolimab
Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
Many osteosarcomas are cured with a variety of combined chemotherapy and surgery, but a significant number will still relapse.VEGF promotes an immunosuppressive microenvironment and contributes to immune checkpoint inhibitor…
- Trial name
- NCT05941325
- Testing
- fruquintinib, Envafolimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai 6th People's Hospital
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
This is a multicenter open-label, randomized, non-comparative, parallel cohort pivotal study of treatment with envafolimab (cohort A and C) or envafolimab combined with ipilimumab (cohort B and D) in patients with locally…
- Trial name
- ENVASARC (NCT04480502)
- Testing
- Envafolimab, Ipilimumab
- Where
- 30 sites in United States, United Kingdom
- Volunteers
- 207 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Osteosarcoma, Neoadjuvant Therapy
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
Given that osteosarcoma typically presents at an early age and predominantly affects pediatric and adolescent populations, early control of disease progression and the opportunity for complete tumor resection are particularly…
- Conditions
- Osteosarcoma, Neoadjuvant Therapy, Neoadjuvant Chemotherapy, PD-L1 Antibody
- Trial name
- NCT07142863
- Testing
- Envafolimab and neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine